DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2012/0220962 A1 HSU Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2012/0220962 A1 HSU Et Al US 2012022.0962A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0220962 A1 HSU et al. (43) Pub. Date: Aug. 30, 2012 (54) TRANSIDERMAL AND TOPCAL ation-in-part of application No. 09/972,008, filed on ADMINISTRATION OF VITAMINS USING Oct. 4, 2001, now Pat. No. 6,582,724, which is a con BASC PERMEATION ENHANCERS tinuation-in-part of application No. 09/738,410, filed on Dec. 14, 2000, now Pat. No. 6,586,000, which is a (75) Inventors: Tsung-Min HSU, San Diego, CA continuation-in-part of application No. 09/738,395, (US); Nicole T. GRICENKO, San filed on Dec. 14, 2000, now Pat. No. 6,719,997, which Diego, CA (US); Alan T.J. is a continuation-in-part of application No. 09/607, HICKEY, San Diego, CA (US); 982, filed on Jun. 30, 2000, now abandoned, which is a Eric C. JACOBSON, San Diego, continuation-in-part of application No. 09/596,889, CA (US); Rose C. LOBELLO, San filed on Jun. 19, 2000, now Pat. No. 6,455,830, which Diego, CA (US); Jane OBARA, is a continuation-in-part of application No. 09/465, San Diego, CA (US) 098, filed on Dec. 16, 1999, now abandoned. (73) Assignee: TECHNOLOGY RECOVERY Publication Classification SYSTEMS, LLC, (51) Int. C. MINNEAPOLIS, MN (US) A6M 35/00 (2006.01) (21) Appl. No.: 13/468,821 (52) U.S. Cl. ......................................... 604/307; 604/304 (22) Filed: May 10, 2012 (57) ABSTRACT Methods are provided for enhancing the permeability of skin Related U.S. Application Data or mucosal tissue to topical or transdermal application of (60) Continuation of application No. 12/343,000, filed on pharmacologically or cosmeceutically active agents. The Dec. 23, 2008, which is a continuation of application methods entail the use of a base in order to increase the flux of No. 10/860,887, filed on Jun. 3, 2004, now abandoned, the active agent through a body Surface while minimizing the which is a division of application No. 10/177,436, filed organic base. Compositions and transdermal systems are also on Jun. 20, 2002, now abandoned, which is a continu described. US 2012/O220962 A1 Aug. 30, 2012 TRANSIDERMAL AND TOPCAL through the skin. As will be appreciated by those in the field, ADMINISTRATION OF VITAMINS USING chemical enhancers are compounds that are administered BASIC PERMEATION ENHANCERS along with the drug (or in some cases the skin may be pre treated with a chemical enhancer) in order to increase the CROSS-REFERENCE TO RELATED permeability of the stratum corneum, and thereby provide for APPLICATIONS enhanced penetration of the drug through the skin. Ideally, Such chemical penetration enhancers or “permeation enhanc 0001. This application is a continuation of U.S. Ser. No. ers, as the compounds are referred to herein, are compounds 12/343,000 filed on Dec. 23, 2008. U.S. Ser. No. 12/343,000 that are innocuous and serve merely to facilitate diffusion of is a continuation of Ser. No. 10/860,887, filed on Jun. 3, 2004. the drug through the stratum corneum. The permeability of Ser. No. 10/860,887 is a divisional of U.S. Ser. No. 10/177, many therapeutic agents with diverse physicochemical char 436 filed on Jun. 20, 2002. U.S. Ser. No. 10/177,436 is a acteristics may be enhanced using these chemical enhance continuation in part of U.S. Ser. No. 09/972,008 filed on Oct. ment means. However, there are skin irritation and sensitiza 4, 2001 and now issued as U.S. Pat. No. 6,582,724, which is tion problems associated with high levels of certain a continuation in part of U.S. Ser. No. 09/738.410 filed on enhancers. Dec. 14, 2000 and now issued as U.S. Pat. No. 6,586,000, 0006. Accordingly, although there are many chemical which is a continuation in part of U.S. Ser. No. 09/569,889 methods of enhancing permeation, there remains an ongoing filed on May 11, 2000 and now abandoned, which is a con need for a method that is highly effective in increasing the rate tinuation in part of U.S. Ser. No. 09/465,098 filed on Dec. 16, at which a drug permeates the skin, does not result in skin 1999 and now abandoned; and is a continuation in part of U.S. damage, irritation, sensitization, or the like, and can be used Ser. No. 09/738,395 filed on Dec. 14, 2000, which is a con to effect transdermal delivery of even high molecular weight tinuation in part of U.S. Ser. No. 09/607,892 filed on Jun. 30, drugs such as peptides, proteins, and nucleic acids. It has now 2000, now abandoned, the disclosures of which are incorpo been discovered that basic permeation enhancers as described rated herein by reference. hereinare highly effective permeation enhancers, and provide FIELD OF THE INVENTION all of the aforementioned advantages relative to known per meation enhancers. Furthermore, in contrast to many conven 0002 This invention relates generally to the topical and tional enhancers, transdermal administration of drugs with transdermal administration of pharmacologically or cosme basic permeation enhancers, employed at the appropriate lev ceutically active agents, and more particularly relates to els, does not result in Systemic toxicity. methods and compositions for enhancing the flux of pharma cologically active agents through a body Surface by treatment SUMMARY OF THE INVENTION with a basic permeation enhancer. 0007. One aspect of the invention pertains to a method for enhancing the flux of a drug through a body Surface, compris BACKGROUND OF THE INVENTION ing: (a) administering the drug to a localized region of a 0003. The delivery of drugs through the skin provides human patient's body Surface; and (b) administering a basic many advantages; primarily, such a means of delivery is a permeation enhancer to the localized region, the enhancer comfortable, convenient and noninvasive way of administer comprising a pharmaceutically acceptable base and being ing drugs. The variable rates of absorption and metabolism present in an amount effective to provide a pH within the encountered in oral treatment are avoided, and other inherent range of about 8.0-13.0 at the localized region of the body inconveniences, e.g., gastrointestinal irritation and the like, Surface during administration of the drug and to enhance the are eliminated as well. Transdermal drug delivery also makes flux of the drug through the body Surface without causing possible a high degree of control over blood concentrations of damage thereto. The pharmaceutically acceptable base can be any particular drug. an inorganic or an organic base. 0004 Skin is a structurally complex, relatively thick mem 0008 Another aspect of the invention relates to a compo brane. Molecules moving from the environment into and sition for the enhanced delivery of a drug through a body through intact skin must first penetrate the stratum corneum Surface, comprising a formulation of: (a) a therapeutically and any material on its surface. They must then penetrate the effective amount of the drug; (b) a pharmaceutically accept viable epidermis, the papillary dermis, and the capillary walls able base, in an amount effective to provide a pH within the into the blood stream or lymph channels. To be so absorbed, range of about 8.0-13.0 at the body surface during adminis molecules must overcome a different resistance to penetra tration of the drug and to enhance the flux of the drug through tion in each type of tissue. Transport across the skin mem the body Surface without causing damage thereto; and (c) a brane is thus a complex phenomenon. However, it is the cells pharmaceutically acceptable carrier Suitable for topical or of the stratum corneum, which present the primary barrier to transdermal drug administration. In one aspect of the inven absorption of topical compositions or transdermally admin tion the pH is about 8.0-11.5 and in another aspect, the pH is istered drugs. The stratum corneum is a thin layer of dense, about 8.5-10.5. The formulation is typically aqueous. The highly keratinized cells approximately 10-15 microns thick pharmaceutically acceptable base can be an inorganic or an over most of the body. It is believed to be the high degree of organic base. keratinization within these cells as well as their dense packing 0009. Yet another aspect of the invention pertains to a which creates in most cases a Substantially impermeable bar system for the enhanced topical or transdermal administra rier to drug penetration. With many drugs, the rate of perme tion of a drug, comprising: (a) at least one drug reservoir ation through the skin is extremely low without the use of containing the drug and a pharmaceutically acceptable base, Some means to enhance the permeability of the skin. in an amount effective to enhance the flux of the drug through 0005 Numerous chemical agents have been studied as a the body Surface without causing damage thereto; (b) a means means of increasing the rate at which a drug penetrates for maintaining the system in drug and base transmitting US 2012/O220962 A1 Aug. 30, 2012 relationship to the body Surface and forming a body Surface polyurethane, a polyvinyl alcohol, a polyacrylic acid, a poly system interface; and (c) a backing layer that serves as the oxyethylene, a polyvinylpyrrolidone, a poly(hydroxyethyl outer surface of the device during use, wherein the base is methacrylate) (poly(HEMA)), or a copolymer or mixture effective to provide a pH within the range of about 8.0-13.0 at thereof.
Load more

Recommended publications
  • Did You Grow Your Greens?
    Did you Grow your Greens? A Share-Net Resource Book Reading-to-learn curriculum materials to support Language, Natural Sciences, Social Sciences, Life Orientation and Arts & Culture learning areas Acknowledgments The Handprint resource books have been compiled by Rob O’Donoghue and Helen Fox of the Rhodes University Environmental Education and Sustainability Unit. Lawrence Sisitka was responsible for coordination and review, and Kim Ward for editorial review and production for curriculum and Eco-School use. Development funding was provided by CAPE. Cover illustrations are by Tammy Griffin. Knowledge and activity support materials have been adapted from various sources including the Internet, and web addresses have been provided for readers to access any copyright materials directly. Available from Share-Net P O Box 394, Howick, 3290, South Africa Tel (033) 3303931 [email protected] January 2009 ISBN 978-1-919991-05-4 Any part of this resource book may be reproduced copyright free, provided that if the materials are produced in booklet or published form, there is acknowledgment of Share-Net. 1 RESOURCE BOOKS The Handprint Resource Books have been designed for creative educators who are looking for practical ideas to work with in the learning areas of the National Curriculum. The focus is on sustainability practices that can be taken up within the perspective that each learning area brings to environment and sustainability concerns. The resource books are intended to provide teachers with authentic start-up materials for change-orientated learning. The aim is to work towards re-imagining more sustainable livelihood practices in a warming world. Each start-up story was developed as a reading- to-learn account of environmental learning and change.
    [Show full text]
  • Antioxidant and Antibacterial Properties of Endogenous Phenolic Compounds from Commercial Mustard Products
    Antioxidant and antibacterial properties of endogenous phenolic compounds from commercial mustard products By Ronak Fahmi A thesis submitted to the Faculty of Graduate Studies of The University of Manitoba In partial fulfillment of the requirements of the degree of MASTER OF SCIENCE Department of Human Nutritional Sciences University of Manitoba Winnipeg, Canada Copyright © 2016 by Ronak Fahmi Abstract This study investigated the antioxidant and antimicrobial properties of endogenous phenolic compounds in Oriental (Brassica junceae) and yellow (Sinapis alba) mustard seeds. Phenolics in selected Canadian mustard products (seeds/ powder/ flour) were extracted using Accelerated Solvent Extraction (ASE) and their corresponding sinapate profiles were established through HPLC-DAD analysis. The antioxidant capacity of each extract was assessed by DPPH assay and correlated with the total phenolic content (TPC) measured using the Folin–Ciocalteau method. Sinapine was the major phenolic compound in all the samples analysed, with negligible amounts of sinapic acid. The sinapine content, expressed as sinapic acid equivalents (SAE), ranged from 5.36 × 103 ± 0.66 to 14.44 ± 0.43 × 103 µg SAE/g dry weight of the samples, with the highest in the yellow mustard seed extract and lowest in Oriental mustard powder. The level decreased in the following order: yellow mustard seed > Oriental mustard seed > yellow mustard bran > Oriental mustard bran > yellow mustard powder > Oriental mustard powder. Extracts from yellow mustard seeds had the highest TPC (17.61× 103 ± 1.01 µg SAE/g), while Oriental mustard powder showed the lowest TPC with 4.14 × 103 ± 0.92 µg SAE/g. The DPPH radical scavenging activity of mustard methanolic extracts ranged between 36% and 69%, with the following order for both varieties: ground mustard seed > mustard bran > mustard powder.
    [Show full text]
  • K+ Channel Modulators Product ID Product Name Description D3209 Diclofenac Sodium Salt NSAID; COX-1/2 Inhibitor, Potential K+ Channel Modulator
    K+ Channel Modulators Product ID Product Name Description D3209 Diclofenac Sodium Salt NSAID; COX-1/2 inhibitor, potential K+ channel modulator. G4597 18β-Glycyrrhetinic Acid Triterpene glycoside found in Glycyrrhiza; 15-HPGDH inhibitor, hERG and KCNA3/Kv1.3 K+ channel blocker. A4440 Allicin Organosulfur found in garlic, binds DNA; inwardly rectifying K+ channel activator, L-type Ca2+ channel blocker. P6852 Propafenone Hydrochloride β-adrenergic antagonist, Kv1.4 and K2P2 K+ channel blocker. P2817 Phentolamine Hydrochloride ATP-sensitive K+ channel activator, α-adrenergic antagonist. P2818 Phentolamine Methanesulfonate ATP-sensitive K+ channel activator, α-adrenergic antagonist. T7056 Troglitazone Thiazolidinedione; PPARγ agonist, ATP-sensitive K+ channel blocker. G3556 Ginsenoside Rg3 Triterpene saponin found in species of Panax; γ2 GABA-A agonist, Kv7.1 K+ channel activator, α10 nAChR antagonist. P6958 Protopanaxatriol Triterpene sapogenin found in species of Panax; GABA-A/C antagonist, slow-activating delayed rectifier K+ channel blocker. V3355 Vindoline Semi-synthetic vinca alkaloid found in Catharanthus; Kv2.1 K+ channel blocker and H+/K+ ATPase inhibitor. A5037 Amiodarone Hydrochloride Voltage-gated Na+, Ca2+, K+ channel blocker, α/β-adrenergic antagonist, FIASMA. B8262 Bupivacaine Hydrochloride Monohydrate Amino amide; voltage-gated Na+, BK/SK, Kv1, Kv3, TASK-2 K+ channel inhibitor. C0270 Carbamazepine GABA potentiator, voltage-gated Na+ and ATP-sensitive K+ channel blocker. C9711 Cyclovirobuxine D Found in Buxus; hERG K+ channel inhibitor. D5649 Domperidone D2/3 antagonist, hERG K+ channel blocker. G4535 Glimepiride Sulfonylurea; ATP-sensitive K+ channel blocker. G4634 Glipizide Sulfonylurea; ATP-sensitive K+ channel blocker. I5034 Imiquimod Imidazoquinoline nucleoside analog; TLR-7/8 agonist, KCNA1/Kv1.1 and KCNA2/Kv1.2 K+ channel partial agonist, TREK-1/ K2P2 and TRAAK/K2P4 K+ channel blocker.
    [Show full text]
  • Folic Acid, Pyridoxine, and Cyanocobalamin Combination
    ORIGINAL INVESTIGATION Folic Acid, Pyridoxine, and Cyanocobalamin Combination Treatment and Age-Related Macular Degeneration in Women The Women’s Antioxidant and Folic Acid Cardiovascular Study William G. Christen, ScD; Robert J. Glynn, ScD; Emily Y. Chew, MD; Christine M. Albert, MD; JoAnn E. Manson, MD Background: Observational epidemiologic studies indi- and visually significant AMD, defined as confirmed in- cate a direct association between homocysteine concentra- cident AMD with visual acuity of 20/30 or worse attrib- tion in the blood and the risk of age-related macular degen- utable to this condition. eration (AMD), but randomized trial data to examine the effect of therapy to lower homocysteine levels in AMD are Results:Afteranaverageof7.3yearsoftreatmentandfollow- lacking. Our objective was to examine the incidence of AMD up, there were 55 cases of AMD in the combination treat- in a trial of combined folic acid, pyridoxine hydrochloride ment group and 82 in the placebo group (relative risk, 0.66; (vitamin B6), and cyanocobalamin (vitamin B12) therapy. 95% confidence interval, 0.47-0.93 [P=.02]). For visually significant AMD, there were 26 cases in the combination Methods: We conducted a randomized, double-blind, treatment group and 44 in the placebo group (relative risk, placebo-controlled trial including 5442 female health care 0.59; 95% confidence interval, 0.36-0.95 [P=.03]). professionals 40 years or older with preexisting cardio- vascular disease or 3 or more cardiovascular disease risk Conclusions: These randomized trial data from a large factors. A total of 5205 of these women did not have a cohort of women at high risk of cardiovascular disease diagnosis of AMD at baseline and were included in this indicate that daily supplementation with folic acid, pyri- analysis.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0034530 A1 Fantz (43) Pub
    US 2013 0034530A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0034530 A1 Fantz (43) Pub. Date: Feb. 7, 2013 (54) DIETARY SUPPLEMENT COGNITIVE (52) U.S. Cl. ....................................... 424/94.2; 424/643 SUPPORT SYSTEM (57) ABSTRACT (75) Inventor: David Robert Fantz, Denver, CO (US) The present invention relates to a nutritional Supplement composition, comprising a therapeutically effective amounts of Vitamin C, Vitamin D3. Thiamin, Riboflavin, Niacin, Vita (73) Assignee: David R. Fantz, Denver, CO (US) min B6, Folic acid, Vitamin B12, Pantothenic acid, Calcium, Magnesium, Zinc, Chromium, Sugar, Protein, Acetyl-L-Car (21) Appl. No.: 13/456,287 nitine, Dimethylaminoethanol complex, Phosphatidylserine complex, L-Glutamine, N-Acetyl-L-Tyrosine, L-Phenylala nine, Taurine, Methionine, Valine, Isoleucine, 5 Hydrox (22) Filed: Apr. 26, 2012 ytryptophan, L-Taurine, N-Acetyl-Tyrosine, N-Acetyl-L- Cysteine, Alpha Lipoic Acid, Alpha Related U.S. Application Data Glycerylphosphoricholine complex, Bacopa Monnieri extract, Gingko Biloba extract, Passion flower, Lemon Balm, (60) Provisional application No. 61/480.372, filed on Apr. Gotu Kola, Ashwagandha, Choline Bitartrate complex, Panax 29, 2011. Ginseng extract, Turmeric, Organic freeze dried fruit juice blends (concord grape, red raspberry, pineapple, cranberry, Publication Classification acai, pomegranate, acerola cherry, bilberry, lingonberry, black currant, aronia, Sour cherry, black raspberry), Organic (51) Int. Cl. freeze dried greens blends (barley grass, broccoli, beet, car A6 IK33/30 (2006.01) rot, alfalfa, oat), and Protein digestive enzyme blends (Pro A6IP3/02 (2006.01) tease 4.5, peptidase, bromelain, protease 6.0, protease 3.0, L A6IP 25/00 (2006.01) planatrum, B bifidum) in a mixture to provide optimal cog A6 IK38/54 (2006.01) nitive function.
    [Show full text]
  • R Graphics Output
    Dexamethasone sodium phosphate ( 0.339 ) Melengestrol acetate ( 0.282 ) 17beta−Trenbolone ( 0.252 ) 17alpha−Estradiol ( 0.24 ) 17alpha−Hydroxyprogesterone ( 0.238 ) Triamcinolone ( 0.233 ) Zearalenone ( 0.216 ) CP−634384 ( 0.21 ) 17alpha−Ethinylestradiol ( 0.203 ) Raloxifene hydrochloride ( 0.203 ) Volinanserin ( 0.2 ) Tiratricol ( 0.197 ) trans−Retinoic acid ( 0.192 ) Chlorpromazine hydrochloride ( 0.191 ) PharmaGSID_47315 ( 0.185 ) Apigenin ( 0.183 ) Diethylstilbestrol ( 0.178 ) 4−Dodecylphenol ( 0.161 ) 2,2',6,6'−Tetrachlorobisphenol A ( 0.156 ) o,p'−DDD ( 0.155 ) Progesterone ( 0.152 ) 4−Hydroxytamoxifen ( 0.151 ) SSR150106 ( 0.149 ) Equilin ( 0.3 ) 3,5,3'−Triiodothyronine ( 0.256 ) 17−Methyltestosterone ( 0.242 ) 17beta−Estradiol ( 0.24 ) 5alpha−Dihydrotestosterone ( 0.235 ) Mifepristone ( 0.218 ) Norethindrone ( 0.214 ) Spironolactone ( 0.204 ) Farglitazar ( 0.203 ) Testosterone propionate ( 0.202 ) meso−Hexestrol ( 0.199 ) Mestranol ( 0.196 ) Estriol ( 0.191 ) 2,2',4,4'−Tetrahydroxybenzophenone ( 0.185 ) 3,3,5,5−Tetraiodothyroacetic acid ( 0.183 ) Norgestrel ( 0.181 ) Cyproterone acetate ( 0.164 ) GSK232420A ( 0.161 ) N−Dodecanoyl−N−methylglycine ( 0.155 ) Pentachloroanisole ( 0.154 ) HPTE ( 0.151 ) Biochanin A ( 0.15 ) Dehydroepiandrosterone ( 0.149 ) PharmaCode_333941 ( 0.148 ) Prednisone ( 0.146 ) Nordihydroguaiaretic acid ( 0.145 ) p,p'−DDD ( 0.144 ) Diphenhydramine hydrochloride ( 0.142 ) Forskolin ( 0.141 ) Perfluorooctanoic acid ( 0.14 ) Oleyl sarcosine ( 0.139 ) Cyclohexylphenylketone ( 0.138 ) Pirinixic acid ( 0.137 )
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110449 A1 Lorber Et Al
    US 200601 10449A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110449 A1 LOrber et al. (43) Pub. Date: May 25, 2006 (54) PHARMACEUTICAL COMPOSITION Publication Classification (76) Inventors: Richard R. Lorber, Scotch Plains, NJ (US); Heribert W. Staudinger, Union, (51) Int. Cl. NJ (US); Robert E. Ward, Summit, NJ A6II 3/473 (2006.01) (US) A6II 3L/24 (2006.01) Correspondence Address: A6IR 9/20 (2006.01) SCHERING-PLOUGH CORPORATION (52) U.S. Cl. ........................... 424/464; 514/290: 514/540 PATENT DEPARTMENT (K-6-1, 1990) 2000 GALLOPNG HILL ROAD KENILWORTH, NJ 07033-0530 (US) (57) ABSTRACT (21) Appl. No.: 11/257,348 (22) Filed: Oct. 24, 2005 The present invention relates to formulations useful for Related U.S. Application Data treating respiratory disorders associated with the production of mucus glycoprotein, skin disorders, and allergic conjunc (60) Provisional application No. 60/622,507, filed on Oct. tivitis while substantially reducing adverse effects associ 27, 2004. Provisional application No. 60/621,783, ated with the administration of non-selective anti-cholin filed on Oct. 25, 2004. ergic agents and methods of use thereof. US 2006/01 10449 A1 May 25, 2006 PHARMACEUTICAL COMPOSITION example, Weinstein and Weinstein (U.S. Pat. No. 6,086,914) describe methods of treating allergic rhinitis using an anti CROSS REFERENCE TO RELATED cholinergic agent with a limited capacity to pass across lipid APPLICATION membranes, such as the blood-brain barrier, in combination with an antihistamine that is limited in both sedating and 0001. This application claims benefit of priority to U.S.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Nutrition 102 – Class 3
    Nutrition 102 – Class 3 Angel Woolever, RD, CD 1 Nutrition 102 “Introduction to Human Nutrition” second edition Edited by Michael J. Gibney, Susan A. Lanham-New, Aedin Cassidy, and Hester H. Vorster May be purchased online but is not required for the class. 2 Technical Difficulties Contact: Erin Deichman 574.753.1706 [email protected] 3 Questions You may raise your hand and type your question. All questions will be answered at the end of the webinar to save time. 4 Review from Last Week Vitamins E, K, and C What it is Source Function Requirement Absorption Deficiency Toxicity Non-essential compounds Bioflavonoids: Carnitine, Choline, Inositol, Taurine, and Ubiquinone Phytoceuticals 5 Priorities for Today’s Session B Vitamins What they are Source Function Requirement Absorption Deficiency Toxicity 6 7 What Is Vitamin B1 First B Vitamin to be discovered 8 Vitamin B1 Sources Pork – rich source Potatoes Whole-grain cereals Meat Fish 9 Functions of Vitamin B1 Converts carbohydrates into glucose for energy metabolism Strengthens immune system Improves body’s ability to withstand stressful conditions 10 Thiamine Requirements Groups: RDA (mg/day): Infants 0.4 Children 0.7-1.2 Males 1.5 Females 1 Pregnancy 2 Lactation 2 11 Thiamine Absorption Absorbed in the duodenum and proximal jejunum Alcoholics are especially susceptible to thiamine deficiency Excreted in urine, diuresis, and sweat Little storage of thiamine in the body 12 Barriers to Thiamine Absorption Lost into cooking water Unstable to light Exposure to sunlight Destroyed
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0196469 A1 Thys-Jacobs (43) Pub
    US 2005O196469A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0196469 A1 Thys-Jacobs (43) Pub. Date: Sep. 8, 2005 (54) MICRONUTRIENT SUPPLEMENT (22) Filed: Mar. 4, 2004 COMBINATION FOR ACNE TREATMENT AND PREVENTION Publication Classification (76) Inventor: Susan Thys-Jacobs, Larchmont, NY (51) Int. Cl.' ....................... A61 K 31/59; A61 K 31/525; (US) A61K 33/10; A61K 31/19 (52) U.S. Cl. ......................... 424/687; 514/168; 514/251; Correspondence Address: 514/574 GOTTLEB RACKMAN & REISMAN PC 27O MADSON AVENUE 8TH FLOOR (57) ABSTRACT NEW YORK, NY 100160601 A micronutrient Supplement comprising effective amounts (21) Appl. No.: 10/794,729 of calcium, Vitamin D, and folate treats and prevents acne. US 2005/0196469 A1 Sep. 8, 2005 MICRONUTRIENT SUPPLEMENT COMBINATION therapies include benzoyl peroxide which has comedolytic FOR ACNE TREATMENT AND PREVENTION and antibacterial effects, topical antibacterials Such as eryth romycin or clindamycin, azelaic acid, tazaroc, and topical FIELD OF THE INVENTION retinoids. Acne that is resistant to topical treatment requires oral antibiotics or isotretinoin. Indications for isotretinoin 0001. This invention relates to a micronutrient supple include Severe Scarring, acne that is resistant to oral antibi ment in the treatment of acne Vulgaris and inflammation. In otics and acne present for many years that quickly relapses particular, this invention relates to a multi-vitamin and when an oral antibiotic therapy is discontinued. Of note, oral mineral Supplement for improving skin and hair health. isotretinoin is a potent teratogen. Current Standards of acne therapy include the topical descquarnative drugs and antibac BACKGROUND OF THE INVENTION terial agents.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]